Improve the Performance and Lower the Costs of ODT Drug Applications

Article

J.T.Baker® PanExcea™ MC200G performance excipient from Avantor™ Performance Materials (formerly Mallinckrodt Baker) is engineered to reduce your cost-per-tablet.

J.T.Baker® PanExcea™ MC200G performance excipient from Avantor™ Performance Materials (formerly Mallinckrodt Baker) is an orally disintegrating tablet (ODT) building block enabling formulators to develop a direct compression ODT that disintegrates rapidly while offering good taste and texture. PanExcea™ MC200G offers a unique, dense spherical particle shape and morphology to maximize API loading capacity, blend flowability and taste-masking.

An excipient-based solution, PanExcea MC200G is also engineered to reduce cost-per-tablet because it can be produced using standard manufacturing and packaging equipment. This reduces or eliminates the costs of ODT technology licensing and new equipment investment. Read more.
Learn more: www.mallbaker.com/panexcea

Avantor™ Performance Materials
222 Red School Lane
Phillipsburg, NJ 08865
1-855-AVANTOR (within U.S.)
1-908-859-2151 (outside U.S.)
Fax: 908-859-6905

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Related Content